Vitiligo (Investigational)
Highly investigational adjunct for limited stable vitiligo; case reports only; topical calcineurin inhibitors, narrow-band UVB, and ruxolitinib cream remain primary.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for vitiligo. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for vitiligo is highly investigational.
- ¿Qué evidencia existe?
- Tier C (highly investigational). Only anecdotal case reports describe limited repigmentation; there are no randomized controlled trials. Evidence-based options per AAD 2023 guideline include topical calcineurin inhibitors (tacrolimus 0.1 percent), topical ruxolitinib cream (FDA-approved 2022 for nonsegmental vitiligo), topical corticosteroids, narrow-band UVB phototherapy (the most effective non-surgical option), excimer laser, and surgical melanocyte transplantation for stable limited disease. Vitiligo is autoimmune; peripheral leech application is unlikely to address that pathophysiology.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment
- Koebner phenomenon — new vitiligo patches at bite sites (this is the dominant risk in vitiligo)
- Bruising and tenderness for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Post-inflammatory hyperpigmentation or hypopigmentation at bite sites
- Permanent scars at bite sites
- Delay or replacement of effective therapy with risk of disease progression
- Quién no debería considerar esto
- Patients with active progressive vitiligo (new patches in the last 6 months — needs stabilization first)
- Patients with a documented Koebnerization tendency
- Patients with segmental vitiligo (different mechanism — consider melanocyte transplant)
- Patients on topical ruxolitinib (drug interaction unknown)
- Patients with skin malignancy or atypical nevi at proposed sites
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Qué preguntar a su clínico
- Has my vitiligo been stable for at least 6 months with no new lesions?
- Have I tried topical tacrolimus or topical ruxolitinib (Opzelura) — the only FDA-approved nonsegmental vitiligo therapy?
- Have I been offered narrow-band UVB phototherapy or excimer laser?
- Am I a candidate for surgical melanocyte transplantation for stable patches?
- What is my Koebnerization risk, and how does it impact leech therapy decisions?
- What is the realistic effect size with leech therapy versus proven options?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Cuándo buscar atención urgente
- Rapidly progressive new vitiligo patches (suggests active autoimmune flare)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- New vitiligo at the bite site itself (Koebner phenomenon)
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Qué NO significa esto
- This is not FDA-cleared for vitiligo.
- Anecdotal case reports do NOT establish efficacy versus topical ruxolitinib, NB-UVB, or melanocyte transplantation.
- Mechanism rationale does NOT address the autoimmune melanocyte destruction at the root of vitiligo.
- Leech therapy carries a real Koebner risk — new vitiligo patches at bite sites are possible.
- Leech therapy is not a substitute for topical ruxolitinib, NB-UVB phototherapy, or surgical melanocyte transplantation.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- dermatological
- ICD-10
- L80
- Safety tier
- medium
Evidence Summary
Vitiligo management per the AAD 2023 guideline includes topical calcineurin inhibitors (tacrolimus, pimecrolimus), topical corticosteroids, topical ruxolitinib (FDA-approved 2022 for nonsegmental vitiligo), narrow-band UVB phototherapy, and surgical melanocyte transplantation for stable limited disease. No controlled clinical trial of leech therapy for vitiligo has been published; its use is investigational and mechanistic only. The autoimmune pathophysiology (melanocyte destruction) is not addressed by peripheral leech application, and repigmentation is more plausibly achieved with conventional immunomodulation and phototherapy. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Singh K et al. (2018)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active progressive vitiligo (consider stabilization first)
- Segmental vitiligo (different mechanism, consider melanocyte transplant)
- Koebnerization tendency (treatment trauma may extend lesions)
- Concurrent topical ruxolitinib (drug interaction unknown)
- Skin malignancy or atypical nevi at proposed site
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.